These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 3138052)

  • 1. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1987 Dec; 27(6):703-13. PubMed ID: 3138052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute pituitary-ovarian response during chronic luteinizing hormone-releasing hormone agonist administration in polycystic ovarian syndrome.
    Faure N; Lemay A
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):403-10. PubMed ID: 3150825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GnRH agonist administration in polycystic ovary syndrome.
    Buckler HM; Phillips SE; Kovacs GT; Burger HG; Healy DL
    Clin Endocrinol (Oxf); 1989 Aug; 31(2):151-65. PubMed ID: 2514053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term administration of gonadotropin-releasing hormone agonist and dexamethasone: assessment of the adrenal role in ovarian dysfunction.
    Cedars MI; Steingold KA; de Ziegler D; Lapolt PS; Chang RJ; Judd HL
    Fertil Steril; 1992 Mar; 57(3):495-500. PubMed ID: 1531463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
    Berga SL; Yen SS
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-testicular function of prostatic cancer patients during treatment with a gonadotropin-releasing hormone agonist analog. I. Circulating hormone levels.
    Huhtaniemi I; Nikula H; Rannikko S
    J Androl; 1987; 8(6):355-62. PubMed ID: 3123445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
    Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
    Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of sequential administration of octreotide alone and octreotide/growth hormone simultaneously on buserelin stimulated ovarian steroid secretion in women with polycystic ovary syndrome.
    Piaditis GP; Hatziioanidis AH; Trovas GP; Misichronis GS; Kounadi TG; Devetzaki OA; Andronis CK; Rangou DB; Chlouverakis CS
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):595-604. PubMed ID: 8977757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 17-Hydroxyprogesterone response to buserelin testing in the polycystic ovary syndrome.
    Sahin Y; Keleştimur F
    Clin Endocrinol (Oxf); 1993 Aug; 39(2):151-5. PubMed ID: 8396511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin and ovarian steroid production in polycystic ovarian syndrome during suppression with a gonadotropin-releasing hormone agonist.
    Tanbo T; Abyholm T; Magnus O; Henriksen T
    Gynecol Obstet Invest; 1989; 28(3):147-51. PubMed ID: 2509303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of LH suppression in polycystic ovary syndrome.
    Fleming R; Black WP; Coutts JR
    Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disruption of the synchronous secretion of leptin, LH, and ovarian androgens in nonobese adolescents with the polycystic ovarian syndrome.
    Veldhuis JD; Pincus SM; Garcia-Rudaz MC; Ropelato MG; Escobar ME; Barontini M
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3772-8. PubMed ID: 11502810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
    Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
    J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of low-dose GnRH analogue (Buserelin) in the treatment of hirsutism.
    Bertoli A; Fusco A; Magnani A; Marini MA; Di Daniele N; Gatti S; Lauro R
    Exp Clin Endocrinol Diabetes; 1995; 103(1):15-20. PubMed ID: 7621099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.